This page shows what was measured, who it was measured in, and what that does not settle.
What Fosfomycin does in the body
CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae .
4 ) ] .
Why people take it. CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae .
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 2N81MY12TE · read 2026-08-29
Its recorded molecular formula is C3H5Na2O4P, weighing 182.
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 84 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Maternal non-anemic state (Hb ≥11 g/dL)
✗ The study did not show it
Who was studied
NCT05590260
How many people
4857
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Any registered clinical infectious complication after prostate biopsy
✗ The study did not show it
Who was studied
NCT03228108
How many people
1538
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Clinical effectiveness.
✗ The study did not show it
Who was studied
NCT04959331
How many people
1000
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
14-day All-Cause Mortality Rate
✗ The study did not show it
Who was studied
NCT05942157
How many people
810
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4
✗ The study did not show it
Who was studied
NCT02639520
How many people
659
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger
✗ The study did not show it
Who was studied
NCT00994318
How many people
626
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of CONTEPO in patients less than 18 years of age has not been established.”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
On older people, the label states: “Of the 233 patients treated with CONTEPO in Trial 1, 32% (74/233) were 65 years of age and older, including 11.2% (26/233) who were 75 years of age and older.”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Available data from observational studies and pharmacovigilance reports with fosfomycin use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Fosfomycin is present in human milk.”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
On people with reduced liver function, the label states: “Monitor patients with severe hepatic impairment closely for fluid overload and electrolyte abnormalities [see Warnings and Precautions ( 5.1 ), Clinical Pharmacology ( 12.3 )] .”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
On people with reduced kidney function, the label states: “Dosage adjustment is required for patients with estimated CLcr 50 mL/min or less.”
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as for solution, powder, granule, for solution, injection, powder, for solution, given by the oral, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
21 products list this as an active ingredient in the United States drug directory. 21 of them contain it and nothing else.
FDA National Drug Code directory · 40074-0005 · read 2026-08-29
They are sold as granule, granule, for solution, injection, powder, for solution and powder, taken intravenous and oral.
FDA National Drug Code directory · 40074-0005 · read 2026-08-29
11 published labels name it as an active ingredient. 11 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · d101b5d8-bffc-4ee6-b93b-4589fcb8750d · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · d101b5d8-bffc-4ee6-b93b-4589fcb8750d · read 2026-08-29
Contepo is intravenous at 3 DOSAGE FORMS AND STRENGTHS CONTEPO for Injection contains 6 grams of fosfomycin, and is supplied as a white or almost white, sterile powder in single-dose vials, for constitution and further dilution., recorded as fda label in effect 2025-11-04 in the United States.
US prescribing information · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · read 2026-08-30
Recorded price in US: 26.75419 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 8 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Fosfomycin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Fosfomycin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
9 documents were read for this substance.
RNAWiki source record
8 of them state the same bioavailability, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
2N81MY12TE
CAS registry number
23155-02-4
PubChem compound
446987
ChEMBL
CHEMBL1757
ChEBI
28915
WHO international nonproprietary name list entry
3014
RxNorm concept
4550
EMA substance identifier
100000086575
European Chemicals Agency number
245-463-1
DrugBank
DB00828
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA050717, approved 19961219 to ZAMBON SPA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (9)
Q1
On the Fosfomycin label: indicated for what?
"CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . ( 1.1 ) Usage to Reduce Development of Drug-Resistant…": indications and usage on Fosfomycin's label. DailyMed label · 855574f2-39f8-43bc-a3d2-79dbb578cb94 · 2025-11-04
Q2
44 registered trials of Fosfomycin — at which phases?
Registered studies posting no result
38 of 44
44 registered studies of Fosfomycin: 16 phase4, 9 phase3, 7 phase1, 7 phase2, 5 na or unstated, 2 early phase1, 2 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01
204 with a PubMed record
Show the evidence
phase4
16
phase3
9
phase1
7
phase2
7
na or unstated
5
early phase1
2
5 more recorded rows
na
2
completed
24
unknown
10
recruiting
6
terminated
4
recorded 2026-09-01 · last checked 2026-09-04
Q3
4 of Fosfomycin's trials stopped: accrual/recruitment, other?
"One of the study drugs was no longer available on a worldwide level."; 4 of 44 registered studies
Show the evidence
Trial
NCT01931592
terminated; "One of the study drugs was no longer available on a worldwide level."
NCT02099240
terminated; "Not enough patient enrollment and lack of staffing"
NCT03697993
terminated; "inadequate enrollment."
NCT05254808
terminated; "Insufficient participating sites, and insufficient participants from participating sites mainly due to COVID-19 workload. The number of necessary participants could not be reached within the anticipated timelines and the allocated budget."
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Fosfomycin used Fosfomycin 3 g — over how long?
Human studies of Fosfomycin used "Fosfomycin 3 g". ClinicalTrials.gov · 2026-09-01
4 recorded entries; human; also "fosfomycin-trometamol 3 g", "Fosfomycin Tromethamine 3G Sachet", "Fosfomycin 3000 MG"
Show the evidence
human
NCT01803191
Fosfomycin 3 g
NCT01931592
fosfomycin-trometamol 3 g
NCT04209192
Fosfomycin Tromethamine 3G Sachet
NCT06017479
Fosfomycin 3000 MG
recorded 2026-09-01 · last checked 2026-09-04
Q5
Which 16 trials of Fosfomycin posted no result?
Posted no result
16 of 16 completed trials
Registrations
NCT01488955, NCT02178254, NCT01820897, NCT01803191, NCT02639520 and NCT03235947, and 10 more
Completion dates
oldest 2014-07; newest 2024-02-20
Show the evidence
Trial
NCT01488955
2014-07
NCT02178254
2014-10
NCT01820897
2015-03
NCT01803191
2016-01-25
NCT02639520
2017-06-29
NCT03235947
2017-11-06
10 further recorded trials
NCT03709927
2018-08-21
NCT03453177
2019-05-24
NCT03151603
2019-06-20
NCT03176563
2019-08-20
NCT01431326
2019-11
NCT03294395
2020-06-05
NCT03228108
2021-09-26
NCT05260554
2022-02-18
NCT04209192
2023-04-01
NCT05545137
2024-02-20
Q6
At the median, Fosfomycin's trials enrolled 152 people — anything larger?
Median enrolment
152
Largest enrolment
5000
Registered trials counted
44
Q7
What do 60 spontaneous reports say about Fosfomycin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Fosfomycin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 60 reaction mentions were counted: abortion spontaneous 10; hypersensitivity 9; urinary tract infection 8; renal impairment 6. FAERS via Open Targets · CHEMBL1200331 · 2026-06-24
Show the evidence
abortion spontaneous
10
hypersensitivity
9
urinary tract infection
8
renal impairment
6
colitis
5
agranulocytosis
5
4 more recorded rows
cholecystitis infective
5
foetal heart rate decreased
4
rash maculo-papular
4
toxic skin eruption
4
recorded 2026-06-24 · last checked 2026-09-04
Q8
Which 10 reactions does Fosfomycin's label not list?
Drug Interaction Studies In Vitro Studies Fosfomycin at clinically relevant concentrations does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.
pharmacokinetics
Fosfomycin does not induce CYP1A2, CYP2B6, and CYP3A4.
pharmacokinetics
Fosfomycin is not a substrate for P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1 or MATE2-K.
pharmacokinetics
Fosfomycin inhibits MATE1 and MATE2-K with the observed IC50 values of 30.0 mM (4142 mcg/mL) and 56.4 mM (7787 mcg/mL), respectively.
pharmacokinetics
Fosfomycin does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, and OCT2.
clinical_pharmacology
Drug Interaction Studies In Vitro Studies Fosfomycin at clinically relevant concentrations does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.
2 more recorded rows
Interaction statementclinical_pharmacology
Fosfomycin does not induce CYP1A2, CYP2B6, and CYP3A4.
Interaction statementclinical_pharmacology
Fosfomycin is not a substrate for P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1 or MATE2-K.
ChEMBL 37 — CC BY-SA 3.0 Unported · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.